BCL-2 is dispensable for thrombopoiesis and platelet survival

HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia

(2015) Gabriela Brumatti et al.   Oncotarget

Platelet bioreactor-on-a-chip

(2014) J. N. Thon et al.   BLOOD

Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan

(2014) Z.-J. Liu et al.   BLOOD

The role of apoptosis in megakaryocytes and platelets

(2014) Benjamin T. Kile   BRITISH JOURNAL OF HAEMATOLOGY

Loss of Bak enhances lymphocytosis but does not ameliorate thrombocytopaenia in BCL-2 transgenic mice

(2014) C J Vandenberg et al.   CELL DEATH AND DIFFERENTIATION

Expandable Megakaryocyte Cell Lines Enable Clinically Applicable Generation of Platelets from Human Induced Pluripotent Stem Cells

(2014) Sou Nakamura et al.   Cell Stem Cell

A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors

(2014) Gordana Vlahovic et al.   INVESTIGATIONAL NEW DRUGS

Proteasome function is required for platelet production

(2014) Dallas S. Shi et al.   JOURNAL OF CLINICAL INVESTIGATION

Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation

(2014) A. P. Ng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL

(2014) Michael F. T. Koehler et al.   ACS Medicinal Chemistry Letters

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

Platelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways

(2014) Emma C. Josefsson et al.   Nature Communications

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway

(2013) M J Roy et al.   BRITISH JOURNAL OF PHARMACOLOGY

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

(2013) Jeffrey R. Infante et al.   EUROPEAN JOURNAL OF CANCER

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance

(2013) Steve A Maxwell et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

HLA-Universal Platelet Transfusions Prevent Platelet Refractoriness in a Mouse Model

(2013) Christiane Gras et al.   HUMAN GENE THERAPY

The incredible journey: From megakaryocyte development to platelet formation

(2013) Kellie R. Machlus et al.   JOURNAL OF CELL BIOLOGY

Synthetic microvessels

(2013) J. A. López et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Mcl-1 and Bcl-xL coordinately regulate megakaryocyte survival

(2012) M. A. Debrincat et al.   BLOOD

Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages

(2012) T Kodama et al.   CELL DEATH AND DIFFERENTIATION

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets

(2011) Emma C. Josefsson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Bendamustine: something old, something new

(2010) Nishant Tageja et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Thrombocytopenia Exacerbates Cholestasis-Induced Liver Fibrosis in Mice

(2010) Takahiro Kodama et al.   GASTROENTEROLOGY

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Beyond Clotting: The Powers of Platelets

(2010) M. Leslie   SCIENCE

Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function

(2009) S. M. Schoenwaelder et al.   BLOOD

Brief Report: Increased Apoptosis in Advanced Atherosclerotic Lesions of Apoe −/− Mice Lacking Macrophage Bcl-2

(2008) Edward Thorp et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH